NCT05274087

Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy Volunteers

A Randomized, Double-Blind, Three-Period Crossover Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: AbbVie · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The objective of this study is to assess the impact of different warm-up times of risankizumab autoinjector (AI) on the participant injection site pain experience in healthy adult volunteers.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	Risankizumab	Subcutaneous autoinjector

Timeline

• Start date: 2020-09-15
• Primary completion: 2021-04-07
• Completion: 2021-04-07
• First posted: 2022-03-10
• Last updated: 2022-03-10

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study